Humana Inc: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Jul 27, 2022 and accepted by EDGAR at Jul 27, 2022, 15:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $23.66bn | us-gaap:Revenues |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $47.63bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $3.17bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $6.06bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | $1.22bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | $2.50bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $101.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $191.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $427.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $713.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | $696.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | $1.63bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | $5.48 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | $12.77 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | $5.50 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | $12.83 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 127,084,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 127,279,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | $1.26bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $574.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2022-01-01 to 2022-06-30 | $191.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months2022-01-01 to 2022-06-30 | $1.03bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-06-30 | $5.15bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $27.22bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $46.82bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $17.84bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $31.31bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $11.29bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-06-30 | $1.54bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2022-06-30 | $15.51bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
| Shares outstanding | At period end2022-06-30 | 126,553,698 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000049071-22-000057. Last ingested by Listed: Nov 6, 2026, 14:15 ET. Listed shows no prices and gives no investment advice.